Effect of Antituberculosis Drug Therapy on Liver Enzyme CYP2C9
Author Information
Author(s): Melvin G, Shewade DG, Saka VK, Adithan C
Primary Institution: Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India
Hypothesis
Does antituberculosis therapy induce the CYP2C9 enzyme in tuberculosis patients with polymorphic CYP2C9 gene?
Conclusion
Antituberculosis therapy induces the CYP2C9 enzyme in TB patients, but significant induction is only observed in the CYP2C9*1*1 genotype.
Supporting Evidence
- The mean ratio of phenytoin/p-HPPH significantly decreased after one month of ATT in CYP2C9*1*1.
- Significant reduction in phenytoin metabolic ratio was found only in the CYP2C9*1*1 genotype.
Takeaway
This study looked at how a tuberculosis treatment affects a liver enzyme that helps break down drugs, finding that it works differently depending on a person's genes.
Methodology
Patients were genotyped for CYP2C9 and their enzyme activity was measured before and after one month of antituberculosis therapy.
Participant Demographics
111 tuberculosis patients (67 male, 44 female)
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website